Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). BioHarvest Sciences's share price for the quarter that ended in Mar. 2026 was €3.56. BioHarvest Sciences's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 22.67 Mil. Therefore, BioHarvest Sciences's market cap for the quarter that ended in Mar. 2026 was €80.70 Mil.
BioHarvest Sciences's quarterly market cap
declined
from Sep. 2025 (€164.77 Mil) to Dec. 2025 (€96.11 Mil) and
declined
from Dec. 2025 (€96.11 Mil) to Mar. 2026 (€80.70 Mil).
BioHarvest Sciences's annual market cap
increased
from Dec. 2023 (€66.54 Mil) to Dec. 2024 (€98.77 Mil) but then
declined
from Dec. 2024 (€98.77 Mil) to Dec. 2025 (€96.11 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. BioHarvest Sciences's Enterprise Value for Today is €49.36 Mil.
BioHarvest Sciences (FRA:8MV0) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
BioHarvest Sciences Market Cap Related Terms
BioHarvest Sciences Market Cap Historical Data
* Premium members only.
The historical data trend for BioHarvest Sciences's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:8MV0 vs BRID, BOF, BFNH: Market Cap Comparison
For the Packaged Foods subindustry, BioHarvest Sciences's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioHarvest Sciences Market Cap vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, BioHarvest Sciences's Market Cap distribution charts can be found below:
* The bar in red indicates where BioHarvest Sciences's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
BioHarvest Sciences's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioHarvest Sciences (FRA:8MV0) has a Market Cap of €54.74 Mil as of Jul. 21, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on BioHarvest Sciences and its competitors. According to the industry distribution chart, BioHarvest Sciences ranks #1206 out of 2048 companies in the Consumer Packaged Goods industry, placing it in the top 58.9%.
Is BioHarvest Sciences' Market Cap too high?
BioHarvest Sciences' current Market Cap is €54.74 Mil. Based on the distribution chart, BioHarvest Sciences ranks #1206 out of 2048 companies in the Consumer Packaged Goods industry, which is below the industry midpoint. Overall, BioHarvest Sciences has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioHarvest Sciences' Market Cap compare to BRID and BOF?
According to the Consumer Packaged Goods industry distribution chart, BioHarvest Sciences ranks #1206 out of 2048 companies for Market Cap. This places BioHarvest Sciences in the lower half of its industry. The industry median Market Cap is 101.73. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Consumer Packaged Goods company?
The median Market Cap among Consumer Packaged Goods companies is 101.73, based on 2,048 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on BioHarvest Sciences and its competitors. For the Consumer Packaged Goods industry, the median Market Cap is 101.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioHarvest Sciences's current Market Cap is €54.74 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioHarvest Sciences stock overvalued right now?
Based on GuruFocus' analysis, BioHarvest Sciences (FRA:8MV0) is currently considered Possible Value Trap. The stock's GF Value™ is €6.88, compared to a current price of €2.20 — trading 68% below its estimated fair value. The current Market Cap is €54.74 Mil. BioHarvest Sciences' overall GF Score™ is 63/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For BioHarvest Sciences (FRA:8MV0), the current Market Cap is €54.74 Mil as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioHarvest Sciences (FRA:8MV0) Overvalued in 2026?
Based on GuruFocus' analysis, BioHarvest Sciences stock appears to be undervalued.
The current stock price of €2.20 is trading 68% below its estimated GF Value™ of €6.88.
GuruFocus considers BioHarvest Sciences to be Possible Value Trap.
Key valuation signals for FRA:8MV0:
Market Cap: €54.74 Mil
GF Value™: €6.88 vs. price of €2.20 (68% below fair value)
No single metric tells the full story. See the FRA:8MV0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. The Company has two operating segments or business units: the Products business unit and the CDMO Services business unit. In identifying these operating segments, management generally follows the Company's service lines representing its main products and services. The Products Business Unit - Nutraceuticals: Research, development, manufacturing, marketing and sales of science-based health and wellness nutraceutical solutions which are manufactured and sold as dietary supplements, functional food and beverages. The CDMO Services Business Unit - comprising a Contract Development and Manufacturing Operation that offers pharmaceuticals, cosmeceuticals, nutraceuticals, and nutritions.
63GF Score
Get the complete analysis for FRA:8MV0
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8MV0 has been successfully added to your 
